AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses

AstraZeneca is rowing back from its bet on oncolytic viruses. Four years after stepping up its presence in the immuno-oncology field through a five-asset pact with Transgene, the Anglo-Swedish drug developer has scrapped the partnership before moving a candidate into the clinic.